Design and Fabrication of a DNA Vaccine against Brucella Abortus based on recombinant Lactococcus Lactis that Expresses Lumazine Synthase Protein

Document Type : Original Article(s)

Authors

1 PhD Student, Department of Biology, Faculty of Basic Science, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran

2 Professor, Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran

3 Assistant Professor, Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran

Abstract

Background: Vaccination is an efficient and cost-effective way to control brucellosis. This study aims to generate recombinant Lactococcus lactis (L. lactis) with Brucella abortus (B. abortus) BLS cytoplasmic protein.
Methods: The target vector, gene, and signal peptide (pNZ8148-Usp45-BLS) were developed and made in this study. Cloning accuracy was verified by PCR, enzyme digestion, and sequencing. Top10 F Escherichia coli was transformed using the recombinant expression vector. The column plasmid extraction kit selected and eliminated chloramphenicol-effected bacteria from an agar plate. In electroporation, Lactococcus lactis bacteria received the recombinant vector. Both SDS-PAGE and RT-PCR confirmed the transition.
Findings: To confirm the correctness of cloning and to confirm the presence of the BLS gene in the pNZ8148 vector, PCR and enzymatic digestion were performed. Observation of the BLS gene fragment with a length of 477 bp and plasmid pNZ8148 - Usp45 without the BLS gene fragment with a length of 2997 bp, the cloning of the BLS gene fragment was confirmed. Also, in the study conducted by the nanodrop device, the concentration of the extracted plasmid was estimated at 848.9 ng/µl and the degree of purity was 2.07. The results of RT-PCR indicated the success of the BLS gene transformation of Brucella abortus in L. lactis bacteria. Also, a single protein band of 18 kDa was observed in transformed L. lactis.
Conclusion: The present study showed that the BLS gene of the probiotic L. lactis transfected with pNZ8148-Usp45-BLS is expressed by electroporation.

Highlights

Abbas Doosti: Google Scholar

Keywords

Main Subjects

References

  1. Dadar M, Tiwari R, Sharun K, Dhama K. Importance of brucellosis control programs of livestock on the improvement of one health. Vet Q 2021; 41(1): 137-51.
  2. Vitry MA, Hanot Mambres D, De Trez C, Akira S, Ryffel B, Letesson JJ, et al. Humoral immunity and CD4+ Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis. J Immunol 2014; 192(8): 3740-52.
  3. Darbandi A, Koupaei M, Navidifar T, Shahroodian S, Heidary M, Talebi M. Brucellosis control methods with an emphasis on vaccination: a systematic review. Expert Rev Anti Infect Ther 2022; 20(7): 1025-35.
  4. Shirdast H, Ebrahimzadeh F, Taromchi AH, Mortazavi Y, Esmaeilzadeh A, Sekhavati MH, et al. Recombinant Lactococcus lactis displaying Omp31 antigen of Brucella melitensis can induce an immunogenic response in BALB/c mice. Probiotics Antimicrob Proteins 2021; 13(1): 80-9.
  5. Yousefi S, Abbassi-Daloii T, Sekhavati MH, Tahmoorespur M. Evaluation of immune responses induced by polymeric OMP25-BLS Brucella antigen. Microb Pathog 2018; 115: 50-6.
  6. Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, et al. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2002; 70(5): 2507-11.
  7. Skwarczynski M, Toth I. Non-invasive mucosal vaccine delivery: advantages, challenges and the future. Expert Opin Drug Deliv 2020; 17(4): 435-7.
  8. Rueckert C, Guzmán CA. Vaccines: From empirical development to rational design. PLoS Pathog 2012;
    8(11): e1003001.
  9. Szatraj K, Szczepankowska AK, Chmielewska-Jeznach M. Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts. J Appl Microbiol 2017; 123(2): 325-39.
  10. de Castro CP, Drumond MM, Batista VL, Nunes A, Mancha-Agresti P, Azevedo V. Vector development timeline for mucosal vaccination and treatment of disease using Lactococcus lactis and design approaches of next generation food grade plasmids. Front Microbiol 2018; 9: 1805.
  11. Cohen SN, Chang ACY, Hsu L. Nonchromosomal antibiotic resistance in bacteria: Genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci U S A 1972; 69(8): 2110-4.
  12. Mahmoudi Vashian Z, Doosti Z. Cloning and gene expression of ureG gene as a DNA vaccine candidate against helicobacter pylori [in Persian]. J Guilan Univ Med Sci 2017; 26(102): 20-9.
  13. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS 2009; 11(4): 671.
  14. da Silva AJ, Zangirolami TC, Novo-Mansur MTM, de Campos Giordano R, Martins EAL. Live bacterial vaccine vectors: an overview. Braz J Microbiol 2014; 45(4): 1117-29.
  15. Pasquevich KA, Ibañez AE, Coria LM, García Samartino C, Estein SM, Zwerdling A, et al. An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice. PLoS One 2011; 6(1): e16203.
  16. Sanakkayala N, Sokolovska A, Gulani J, HogenEsch H, Sriranganathan N, Boyle SM, et al. Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinantBrucella abortusRB51. Clin Vaccine Immunol 2005; 12(12): 1429-36.
  17. Velikovsky CA, Goldbaum FA, Cassataro J, Estein S, Bowden RA, Bruno L, et al. Brucellalumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged withBrucella abortus544 independently of the adjuvant formulation used. Infect Immun 2003; 71(10): 5750-5.
  18. Zhao Z, Li M, Luo D, Xing L, Wu S, Duan Y, et al. Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. Vaccine 2009; 27(38): 5214-9.
  19. Leya M, Kim WK, Cho JS, Yu EC, Kim YJ, Yeo Y, et al. Vaccination of goats with a combinationSalmonellavector expressing fourBrucellaantigens (BLS, PrpA, Omp19, and SOD) confers protection againstBrucella abortusinfection. J Vet Sci 2018; 19(5): 643-52.
  20. Rezaei M, Rabbani Khorasgani M, Aliramaei MR. Recombinant lactococcus, a new approach to oral vaccines [in Persian]. J Arak Univ Med Sci 2020, 23(6): 786-805.‏
  21. Diaz-Dinamarca DA, Hernandez C, Escobar DF, Soto DA, Muñoz GA, Badilla JF, et al. Mucosal vaccination with Lactococcus lactis-secreting surface immunological protein induces humoral and cellular immune protection against group B Streptococcus in a Murine model. Vaccines (Basel) 2020; 8(2): 146.
  22. Rezaei M, Rabbani-Khorasgani M, Zarkesh-Esfahani SH, Emamzadeh R, Abtahi H. Lactococcus-based vaccine against brucellosis: IgG immune response in mice with rOmp16-IL2 fusion protein. Arch Microbiol 2021; 203(5): 2591-6.‏
  23. Mohammadi E, Golchin M. High protection of mice against Brucella abortus by oral immunization with recombinant probiotic Lactobacillus casei vector vaccine, expressing the outer membrane protein OMP19 of Brucella species. Comp Immunol Microbiol Infect Dis 2020; 70: 101470.
  24. Sáez D, Fernández P, Rivera A, Andrews E, Oñate A. Oral immunization of mice with recombinant Lactococcus lactis expressing Cu, Zn superoxide dismutase of Brucella abortus triggers protective immunity. Vaccine 2012; 30(7): 1283-90.
Journal of Isfahan Medical School
Volume 41, Issue 738
2nd Week, December
November and December 2023
Pages 872-883

Files

History

  • Receive Date: 21 January 2023
  • Revise Date: 22 November 2023
  • Accept Date: 25 November 2023

Share

How to cite

Statistics